No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 16
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Mineralys Therapeutics, Inc. (MLYS) stock was $21.95 as of Oct 6, 2026, 4:00 PM EDT, down 5.79% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -38.6% · 3-year avg +33.3%/yr
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone.
Biotechnology · Radnor, PA
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.53
Revenue Est.
N/A
Last Quarter Results
EPS
$-2.85
vs Estimate
$-0.54
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MLYS | $1.94B | $21.95 | -5.79% | -38.64% | N/A | N/A | N/A |
| 2ESTA | $1.92B | $65.29 | -1.78% | +60.08% | -1.56% | N/A | vs MLYS |
| 3AXGN | $1.95B | $36.31 | -2.44% | +107.44% | +19.40% | +15.98% | vs MLYS |
| 4VIR | $1.96B | $11.60 | -1.53% | +104.88% | -19.71% | N/A | vs MLYS |
| 5INSP | $1.97B | $68.20 | -3.60% | -7.58% | -21.38% | N/A | vs MLYS |
| 6FTRE | $1.98B | $20.78 | -1.56% | +122.53% | N/A | N/A | vs MLYS |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 8 analysts
Average Price Target
$48.50
+121.0% upside
Low
$30.00
Current
$21.95
High
$56.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.62 | $-0.55 | $-0.47 | 5 |
| Quarter ending Dec 2026 | $-0.69 | $-0.61 | $-0.56 | 5 |
| Quarter ending Mar 2027 | $-0.75 | $-0.75 | $-0.75 | 3 |
| Quarter ending Jun 2027 | $-0.55 | $-0.55 | $-0.55 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.60 | $-4.49 | $-4.44 | 6 |
| FY 2027 | $-3.50 | $-2.43 | $-1.52 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $2.00M | $2.00M | $2.00M | 1 |
| Quarter ending Jun 2027 | $14.86M | $14.86M | $14.86M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $317225.00 | $557143.00 | $738321.00 | 5 |
| FY 2027 | $81.29M | $88.68M | $96.07M | 6 |
